Vinay Prasad was reinstated as the head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA) on 11 August. He had resigned on 29 July.1 “At the FDA’s ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.